DK2605769T3 - Benzoquinonderivater til behandling af mitochondriske øjensygdomme - Google Patents
Benzoquinonderivater til behandling af mitochondriske øjensygdomme Download PDFInfo
- Publication number
- DK2605769T3 DK2605769T3 DK11748898.1T DK11748898T DK2605769T3 DK 2605769 T3 DK2605769 T3 DK 2605769T3 DK 11748898 T DK11748898 T DK 11748898T DK 2605769 T3 DK2605769 T3 DK 2605769T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- mitochondrial
- compounds
- eye
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
Claims (5)
1. Forbindelse repræsenteret af den almene formel (I)
(i) og enantiomererne, tautomererne, solvaterne eller farmaceutisk acceptable salte deraf, hvor R1 er en substituent repræsenteret af formlen (II):
(il) hvor R5 og R6 begge er hydrogenatomer, eller R5 er et hydrogenatom og R6 er en ethylgruppe, eller R5 og R6 begge er methylgrupper, R2 er en methylgruppe, R3 er en methoxygruppe, og R4 er en methoxygruppe; til anvendelse ved behandling af en mitochondrisk sygdom, hvor den mitochondriske sygdom er valgt blandt gruppen bestående af Lebers arvelige optisk neuropati (LHON), autosomal dominant optisk atrofi (DOA), makula-degeneration, glaucoma, retinopati, katarakt og synspapildrusen (ODD).
2. Forbindelse til anvendelse ifølge krav 1, hvor R5 og R6 begge er hydrogenatomer.
3. Forbindelse til anvendelse ifølge krav 2, hvor forbindelsen indgives oralt.
4. Forbindelse til anvendelse ifølge krav 3, hvor den mitochondriske sygdom er valgt blandt gruppen bestående af Lebers arvelige optisk neuropati (LHON), autosomal dominant optisk atrofi (DOA) makuladegeneration og glaucoma.
5. Anvendelse af en forbindelse ifølge den almene formel (I)
(i) hvor R1 til R4 er defineret som i krav 1 til fremstilling af et lægemiddel i behandlingen af en mitochondrisk sygdom, hvor den mitochondriske sygdom er valgt blandt gruppen bestående af Lebers arvelige optisk neuropati (LHON), autosomal dominant optisk atrofi (DOA), makuladegeneration, glaucoma, retinopati, katarakt og synspapildrusen (ODD).
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37397210P | 2010-08-16 | 2010-08-16 | |
EP10008542 | 2010-08-16 | ||
US201061424978P | 2010-12-20 | 2010-12-20 | |
EP10015842 | 2010-12-20 | ||
US201161473835P | 2011-04-11 | 2011-04-11 | |
EP11003037 | 2011-04-11 | ||
PCT/EP2011/004123 WO2012022468A2 (en) | 2010-08-16 | 2011-08-16 | Benzoquinone derivatives as modulators of mitchondrial function |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2605769T3 true DK2605769T3 (da) | 2016-10-24 |
Family
ID=45605465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11748898.1T DK2605769T3 (da) | 2010-08-16 | 2011-08-16 | Benzoquinonderivater til behandling af mitochondriske øjensygdomme |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2605769B1 (da) |
CY (1) | CY1118134T1 (da) |
DK (1) | DK2605769T3 (da) |
ES (1) | ES2588770T3 (da) |
HR (1) | HRP20161407T1 (da) |
HU (1) | HUE030595T2 (da) |
PL (1) | PL2605769T3 (da) |
PT (1) | PT2605769T (da) |
RS (1) | RS55173B1 (da) |
SI (1) | SI2605769T1 (da) |
SM (1) | SMT201600345B (da) |
WO (1) | WO2012022468A2 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014039862A1 (en) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
WO2018078922A1 (ja) * | 2016-10-24 | 2018-05-03 | 国立大学法人福井大学 | 白内障の予防剤、治療剤、およびこれらを製造するためのhat阻害剤の使用 |
JP7104048B2 (ja) | 2017-01-13 | 2022-07-20 | セルラー リサーチ, インコーポレイテッド | 流体チャネルの親水性コーティング |
MX2019008542A (es) * | 2017-01-18 | 2019-11-05 | Schlumberger Technology Bv | Sistema de circulacion ininterrumpida para mantener la presion de fondo de pozo. |
KR20220078644A (ko) | 2019-10-04 | 2022-06-10 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 미토콘드리아 질환 치료를 위한 바티퀴논의 퀴논-, 히드로퀴논- 및 나프토퀴논-유사체 |
WO2021211436A1 (en) * | 2020-04-13 | 2021-10-21 | Travecta Therapeutics Pte. Ltd. | Idebenone compounds |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5919930B2 (ja) | 1974-05-02 | 1984-05-09 | 武田薬品工業株式会社 | キノン酸誘導体の製造法 |
JPS51128932A (en) | 1975-04-30 | 1976-11-10 | Takeda Chem Ind Ltd | Organic compounds |
JPS56150014A (en) | 1980-04-21 | 1981-11-20 | Takeda Chem Ind Ltd | Antiallergic agent |
JPS5877839A (ja) * | 1981-11-02 | 1983-05-11 | Takeda Chem Ind Ltd | 安定な微細結晶およびその製造法 |
ATE64921T1 (de) * | 1985-04-08 | 1991-07-15 | Takeda Chemical Industries Ltd | Benzochinonderivate, ihre herstellung und verwendung. |
EP0788793A1 (en) * | 1996-02-01 | 1997-08-13 | Takeda Chemical Industries, Ltd. | Idebenone for the treatment of dementia |
CA2252519A1 (en) * | 1996-07-11 | 1998-01-22 | Keisuke Hirai | Use of idebenone and analogues against beta amyloid induced cytotoxicity |
TWI246421B (en) | 1998-12-03 | 2006-01-01 | Alcon Mfg Ltd | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
US7977388B2 (en) | 2005-03-21 | 2011-07-12 | Santhera Pharmaceuticals (Schweiz) Ag | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of muscular dystrophies |
EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
EP1891946A1 (en) | 2006-08-14 | 2008-02-27 | Santhera Pharmaceuticals (Schweiz) AG | Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone |
US20100099775A1 (en) | 2008-10-17 | 2010-04-22 | Alpharx Inc. | Method for ameliorating of post-anesthetic recovery |
US20100130619A1 (en) | 2008-11-24 | 2010-05-27 | Joseph Schwarz | Pharmaceutical composition for parenteral administration of idebenone |
US20100129431A1 (en) | 2008-11-24 | 2010-05-27 | Alpharx Inc. | Idebenone composition for the treatment of neurological disorders |
US20100215725A1 (en) | 2009-02-20 | 2010-08-26 | Joseph Schwarz | Pharmaceutical composition containing idebenone for the treatment of liver disorders |
-
2011
- 2011-08-16 WO PCT/EP2011/004123 patent/WO2012022468A2/en active Application Filing
- 2011-08-16 HU HUE11748898A patent/HUE030595T2/en unknown
- 2011-08-16 PL PL11748898T patent/PL2605769T3/pl unknown
- 2011-08-16 SI SI201130942A patent/SI2605769T1/sl unknown
- 2011-08-16 RS RS20160776A patent/RS55173B1/sr unknown
- 2011-08-16 DK DK11748898.1T patent/DK2605769T3/da active
- 2011-08-16 ES ES11748898.1T patent/ES2588770T3/es active Active
- 2011-08-16 PT PT117488981T patent/PT2605769T/pt unknown
- 2011-08-16 EP EP11748898.1A patent/EP2605769B1/en active Active
-
2016
- 2016-10-03 SM SM201600345T patent/SMT201600345B/it unknown
- 2016-10-21 CY CY20161101059T patent/CY1118134T1/el unknown
- 2016-10-27 HR HRP20161407TT patent/HRP20161407T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CY1118134T1 (el) | 2017-06-28 |
WO2012022468A2 (en) | 2012-02-23 |
EP2605769B1 (en) | 2016-07-27 |
SMT201600345B (it) | 2016-11-10 |
PL2605769T3 (pl) | 2017-01-31 |
HRP20161407T1 (hr) | 2016-12-02 |
ES2588770T3 (es) | 2016-11-04 |
HUE030595T2 (en) | 2017-05-29 |
SI2605769T1 (sl) | 2016-10-28 |
PT2605769T (pt) | 2016-11-02 |
EP2605769A2 (en) | 2013-06-26 |
WO2012022468A3 (en) | 2012-06-28 |
RS55173B1 (sr) | 2017-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2605769T3 (da) | Benzoquinonderivater til behandling af mitochondriske øjensygdomme | |
Hargreaves | Coenzyme Q10 as a therapy for mitochondrial disease | |
US20200062712A1 (en) | Aldehyde trapping compounds and uses thereof | |
KR102396714B1 (ko) | 세포 생존력을 향상시키기 위한 조성물 및 이의 사용 방법 | |
JP6876047B2 (ja) | ミトコンドリアの活性酸素種(ros)産生に関連する疾患の治療のための化合物 | |
CA3032609A1 (en) | Aldehyde trapping compounds and methods of use thereof | |
Kuang et al. | Effects of Ginkgo biloba extract on A53T α-synuclein transgenic mouse models of Parkinson’s disease | |
AU7691798A (en) | Vitamin d analogues and their neuronal effects | |
EP2624821B1 (en) | Combination therapy for the treatment of depression and other non-infectious diseases | |
JP7296472B2 (ja) | プリドピジンを使用したミトコンドリア関連疾患および障害(それらの症状を含む)の治療 | |
WO2023023397A1 (en) | Methods for inhibiting the progression of neurodegenerative diseases | |
EP3259274B1 (en) | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau | |
US20230165824A1 (en) | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs | |
EP3989962A1 (en) | Combination therapy with acetyl-leucine and miglustat | |
JP2022523919A (ja) | 神経変性疾患を治療するための物質および方法 | |
AU2017388399B2 (en) | Improvement in locomotor activity and increase in longevity of late infantile neuronal ceriod lipofuscinosis subjects by gemfibrozil | |
ITMI20090284A1 (it) | Uso di inibitori della serina palmitoiltrasferasi per la prevenzione e il rallentamento delle degenerazioni retiniche ereditarie e relative composizioni | |
JP2023534878A (ja) | ミトコンドリア複合体i欠損症に関連するミトコンドリア疾患又は機能障害の処置のためのアルベリン又はその誘導体の使用 | |
JP2023504004A (ja) | トラピジルを使用した認知障害の治療 | |
AU2020294943A1 (en) | Use of disulfiram or its derivatives for the treatment of mitochondrial diseases or dysfunction | |
US20220265635A1 (en) | Treatment of neurological disease | |
US11510889B2 (en) | Methods for inhibiting the progression of neurodegenerative diseases | |
US20220096395A1 (en) | Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases | |
KR20220071285A (ko) | 미토콘드리아 기능 향상 및 미토콘드리아 질환 치료를 위한 화합물의 신규 치료적 용도 | |
WO2024008788A1 (fr) | Utilisation de l'ebselen ou l'un de ses derives pour traiter des pathologies ou dysfonctionnements des mitochondries |